Travere Therapeutics Turns a Rare Disease Approval into Two Quarters of Accelerating Sales
The Food and Drug Administration granted Travere Therapeutics full approval for FILSPARI in focal segmental glomerulosclerosis on April 13, 2026, the ...
Last updated: 2026-08-22 19:36:24 ET
The Food and Drug Administration granted Travere Therapeutics full approval for FILSPARI in focal segmental glomerulosclerosis on April 13, 2026, the ...
Industrial slowdown ahead? ECRI says the global industrial cycle is topping out, and that could squeeze freight demand and margins in the quarters ahe...
At the end of the first half of 2026, on the cusp of a major correction in the sector, more than three quarters of the Situational Awareness fund was ...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE